Plant · Scientific monograph
Taraxacum officinale
Dandelion
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Hepatoprotection, Diuretic Research, Antioxidant & Anti-inflammatory, Prebiotic & GI Research
Research overview
Historical use
Taraxacum officinale has been used in European, North American, and East Asian traditional medicine for centuries as a bitter digestive tonic, cholagogue, and diuretic. The root was employed to stimulate bile production and support liver and gallbladder function, while the leaf was used as a diuretic for oedema and urinary complaints. Its traditional diuretic use has been formally recognised by the European Medicines Agency (EMA) under the traditional herbal medicinal product designation (Taraxaci folium monograph) and in the German Commission E monograph.
Modern research context
Preclinical evidence supports hepatoprotective activity of the root, with sesquiterpene lactones and taraxasterol demonstrating attenuation of CCl4-induced liver injury in mouse models [2]; broader hepatoprotective activity across additional toxic challenge models is reported in preclinical reviews [4,5], though no human clinical trial data for hepatoprotective efficacy are available. A pilot clinical study (n=17) found that a single-day protocol of fresh leaf hydroethanolic extract (8 mL three times daily) produced significant increases in urinary frequency and excretion ratio after the first and second doses (with no significant effect observed after the third dose), suggesting diuretic activity with a potentially favourable electrolyte profile due to the leaf's high natural potassium content [1]. Anti-inflammatory effects have been documented in vitro via suppression of NF-κB nuclear translocation and inhibition of pro-inflammatory cytokines (IL-6, IL-8, TNF-α, VCAM-1) in endothelial cell models [3]. Large-scale human RCT data are lacking; clinical claims remain preliminary.
Adverse effects
Generally well tolerated at conventional food and herbal supplement doses in the absence of comorbidities flagged under contraindications and special precautions. Adverse effects reported include mild gastrointestinal upset (nausea, diarrhoea), and rarely, allergic contact dermatitis and respiratory hypersensitivity reactions — particularly in individuals with documented sensitivity to Asteraceae family plants. Infrequent GI adverse effects have been noted in post-marketing surveillance.
Contraindications
Contraindicated in individuals with known hypersensitivity to Taraxacum officinale or other members of the Asteraceae family. Use with caution in individuals with bile duct obstruction, cholangitis, or gallbladder empyema, as the cholagogue action may exacerbate these conditions. Due to the high potassium content of the leaf, caution is warranted in patients taking medications that raise serum potassium — including potassium-sparing diuretics, ACE inhibitors, beta-blockers, digitalis, tacrolimus, cyclosporine, and trimethoprim — as clinically relevant hyperkalaemia may result. Caution is also warranted when co-administered with antidiabetic medications given preclinical glucose-lowering evidence.
Clinical and phytochemical data
Used part
Root (Taraxaci radix) and leaf/herb (Taraxaci herba) — used separately or combined depending on preparation; root primarily used for hepatic and digestive applications, leaf primarily used for diuretic applications
Primary active compounds
Sesquiterpene lactones: taraxacin, taraxacerin, lactucopicrin (root — primary bitter principles, hepatocurative)
Triterpenes/sterols: taraxasterol, taraxasteryl acetate, taraxerol, β-sitosterol, lupeol, α-amyrin, β-amyrin
Flavonoids: luteolin, quercetin, apigenin, rutin, isoquercitrin, isorhamnetin
Phenolic acids: chlorogenic acid, chicoric acid, caffeic acid, ferulic acid, caftaric acid
Polysaccharides: inulin (root — up to 40% of dry root weight in autumn harvest; prebiotic fructan)
Vitamins and minerals: potassium (leaf — contributes to diuretic profile), vitamins A, C, K
Mechanism of action
Hepatoprotection mediated primarily by taraxasterol and sesquiterpene lactones, which modulate the JAK2/STAT3 and JNK signalling pathways and activate the Nrf2/HO-1 antioxidant response element, reducing oxidative stress-mediated hepatocyte injury in preclinical models [4, 5]. Anti-inflammatory activity proceeds through suppression of NF-κB nuclear translocation, inhibiting downstream production of iNOS, VCAM-1, MCP-1, IL-6, IL-8, and TNF-α [3]. Antioxidant activity involves restoration of glutathione (GSH) and elevation of superoxide dismutase (SOD), catalase, and GSH-peroxidase. Diuretic activity of the leaf is attributed in part to its high natural potassium content; the EMA assessment of Taraxaci folium notes that this potassium content may offset kaliuresis associated with the plant's own diuretic action — this has not been confirmed in a controlled pharmacodynamic trial. The root's inulin content functions as a prebiotic fructan, selectively stimulating growth of Bifidobacterium and Lactobacillus species in the colon. Cholagogue and choleretic activity is attributed to bitter sesquiterpene lactones stimulating bile secretion.
Pharmacokinetics
Absorption
No human pharmacokinetic studies are available for Taraxacum officinale preparations. The following is inferred from in vitro and preclinical data only and may not reflect human pharmacology. Phenolic compounds (chlorogenic acid, chicoric acid, luteolin glycosides) are expected to be absorbed in the small intestine following partial hydrolysis by gut enzymes; bioavailability is influenced by food matrix and gut microbiota composition. Inulin (root) is not absorbed in the small intestine and passes intact to the colon where it undergoes fermentation.
Distribution
No human distribution data are available. Lipophilic triterpenes (taraxasterol, β-sitosterol) are expected to distribute to lipid-rich tissues including the liver, consistent with hepatoprotective activity observed in animal models. Flavonoids are likely distributed as glucuronide and sulfate conjugates following hepatic phase II metabolism.
Metabolism
No human metabolic data are available for Taraxacum-specific compounds. Phenolic acids and flavonoids are expected to undergo hepatic phase II metabolism (glucuronidation, sulfation) and colonic microbial biotransformation. Sesquiterpene lactones may interact with cytochrome P450 enzymes; no specific CYP inhibition data for T. officinale are established in humans.
Excretion
No human excretion data are available. Water-soluble phenolic metabolites are expected to be excreted renally; inulin fermentation products (short-chain fatty acids) are largely absorbed in the colon.
Safety and interactions
Drug interactions
No formal clinical drug interaction studies are available for Taraxacum officinale. The EMA assessment of Taraxaci folium identifies a significant potassium-mediated interaction class: due to the high potassium content of the leaf, concomitant use with medications that raise serum potassium should be avoided or closely monitored. Documented interactions from the EMA assessment include: potassium-sparing diuretics, ACE inhibitors, beta-blockers, cyclosporine, tacrolimus, digitalis (digoxin), heparin, trimethoprim, pentamidine, and NSAIDs — all of which may cause clinically relevant hyperkalaemia when combined with high-potassium botanical preparations. Additional theoretical interactions include: (1) additive hypotensive/diuretic effect with loop diuretics and thiazides; (2) possible potentiation of hypoglycaemic agents — preclinical antidiabetic activity has been reported; (3) increased lithium serum levels due to diuretic-mediated reduction in renal lithium clearance; (4) possible effect of leaf vitamin K content on anticoagulant (warfarin) stability, though clinical magnitude is unknown. Patients on any of these medication classes should consult a healthcare provider before use.
Toxicity
In a comprehensive review (Wu et al., 2024, PMID: 39338278), only three adverse reaction case reports were identified in the published literature, all associated with doses substantially exceeding the conventional therapeutic range. No adverse reactions were reported at normal doses in that review. Animal studies indicate low acute toxicity at conventional experimental doses. Contact sensitisation reactions have been documented in individuals with Asteraceae hypersensitivity.
Special precautions
Pregnancy
Insufficient human safety data exist to establish a safety profile during pregnancy. Due to its diuretic and cholagogue activity and the absence of reproductive toxicity data in humans, use of medicinal-dose preparations during pregnancy is not recommended without medical supervision.
Lactation
The NCBI LactMed database states that T. officinale is classified as Generally Recognised as Safe (GRAS) as a food by the FDA. No data exist on excretion of active compounds into breast milk at medicinal doses. Use as a herbal supplement (rather than as a food) during lactation should be discussed with a healthcare provider.
Hepatic impairment
Despite preclinical hepatoprotective findings, the cholagogue activity of the root warrants caution in patients with bile duct obstruction, cholangitis, or cholecystitis. No clinical pharmacokinetic data exist for patients with impaired hepatic function. Use in hepatic disease should only be considered under medical supervision.
Renal impairment
The EMA assessment of Taraxaci folium explicitly excludes patients with renal failure from its safety statement, citing the risk of clinically significant elevation of serum potassium (hyperkalaemia) due to the leaf's high potassium content. Patients with any degree of renal impairment should not use medicinal-dose Taraxacum leaf preparations without direct medical supervision. No human pharmacokinetic data exist for this population.
Sources and references
- [1] - Clare BA, Conroy RS, Spelman K. The diuretic effect in human subjects of an extract of Taraxacum officinale folium over a single day. J Altern Complement Med, 2009. PMID: 19678785
- [2] - Mahesh A et al. Hepatocurative potential of sesquiterpene lactones of Taraxacum officinale on carbon tetrachloride induced liver toxicity in mice. Acta Biol Hung, 2010. PMID: 20519172
- [3] - Jeon D et al. Anti-inflammatory evaluation of Taraxacum officinale in LPS-stimulated human umbilical vein endothelial cells. BMC Complement Altern Med, 2017. PMID: 29187173
- [4] - Hao F et al. Taraxacum: A Review of Ethnopharmacology, Phytochemistry and Pharmacological Activity. Am J Chin Med, 2024. PMID: 38351703
- [5] - Wu J et al. Botany, Traditional Use, Phytochemistry, Pharmacology of Taraxaci herba. Pharmaceuticals (Basel), 2024. PMID: 39338278